Healthcare Industry News: hemodialysis
News Release - September 28, 2006
OmniSonics Appoints Dr. Elvira Lang as Vice President and Chief Medical OfficerWILMINGTON, Mass., Sept. 28 (HSMN NewsFeed) -- OmniSonics Medical Technologies, Inc., a developer of advanced medical devices, has announced the appointment of Dr. Elvira V. Lang to the position of Vice President and Chief Medical Officer.
Dr. Lang most recently served as Chief of Vascular/Interventional Radiology at the Beth Israel Deaconess Medical Center (BIDMC), Boston for the past eight years. In 1999 she was appointed Associate Professor of Radiology at Harvard Medical School. Dr. Lang completed fellowships at the University of California, San Diego, and the Mallinckrodt Institute of Radiology in St. Louis, then joined the faculty at Stanford University, heading the interventional department at the VA Medical Center in Palo Alto for five years. She then directed the Interventional Radiology unit at the University of Iowa Hospitals and Clinics, Iowa, where she also implemented a commercially successful stent development lab before joining the BIDMC as Section Chief in 1998. Dr. Lang is also known for her pioneering NIH-funded studies that suggest the effectiveness of hypnotherapy in controlling pain during surgery.
With extensive experience in all aspects of interventional radiology, Dr. Lang has special experience in revascularization of severe advanced ischemia, sharp recanalization of chronic venous occlusions, pulmonary suction thrombectomy, percutaneous endoscopic methods, and production of custom devices.
Dr. Lang received her M.D. degree, magna cum laude, from the University of Heidelberg School of Medicine where she also served on the faculty.
"We are honored and excited to welcome Dr. Lang to OmniSonics. With her impressive, extensive background, she will play a pivotal role in the development and commercialization of our products for vascular occlusive disease," said Richard Ganz, President and CEO.
"I am pleased to be a part of the OmniSonics team and its emerging OmniWave Technology platform. I look forward to working with OmniSonics to continue to build the company into a successful medical device enterprise," said Dr. Lang.
About OmniSonics Medical Technologies, Inc.
OmniSonics Medical Technologies, Inc., based in Wilmington, MA, is a venture-backed medical device company focused on developing breakthrough products for the treatment of vascular occlusive disease.
About the OmniWave Technology Platform
The Company's first product, the Resolution® System, is based on the Company's patented OmniWave(TM) Technology, the first technology to enable the delivery of low-power acoustic energy around the active length of a small diameter wire in a diseased blood vessel. The Resolution System with OmniWave technology is designed to rapidly reduce occlusive materials to red blood cell size particles without harming healthy tissue.
The Resolution System is cleared in the U.S. for the treatment of thrombosed hemodialysis access grafts. Clearance for use in peripheral vascular disease is expected in 2007. Additional clinical trials are planned for other indications.
Source: OmniSonics Medical Technologies
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.